WHO Raises Concern Over Acute Lack of Weight-Loss Medications

Less than one in 10 people that would benefit from obesity jabs including Wegovy can access them, states the WHO as it issues its initial recommendations on the therapies.

Given in excess of 1,000,000,000 individuals worldwide now obese, it is advocating for more widespread and fairer access to GLP-1 medication.

Based on forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 without intervention.

"The latest guidelines acknowledges that obesity is a chronic disease that can be managed with comprehensive and continuous support," stated WHO director-general Tedros Adhanom Ghebreyesus.

High costs, limited production capacity, and logistical bottlenecks are major barriers to widespread access to the jabs that can assist patients in reducing considerable weight, explains the organization.

Weight-Loss Drug Scarcity

Despite the present most favorable case, the supply of these medications might only reach about 100 million people – under 10% of those who need them, per the WHO.

The advice calls on governments and firms to widen access, by strategies like voluntary licensing.

The intellectual property rights on the active ingredient – the core component of the drug Wegovy – is due to expire in several nations in 2026.

The Way Obesity Jabs Work

These medications replicate a biological compound to slow digestion, suppress the appetite and enhance satiety so people eat less.

Patients typically start to lose weight after several weeks of starting on the weekly injections.

Studies indicates patients may regain a significant portion after a year of halting the medication, when their normal appetite come back.

Being carrying excess weight elevates your chance for experiencing diseases, including diabetes, cardiovascular issues, brain attack, and specific malignancies.

Obesity concerns individuals in all nations and was associated with 3.7 million fatalities worldwide in 2024, per the WHO.